New oral drug INT-210 aims to tame ulcerative colitis Flare-Ups
NCT ID NCT07692165
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests an experimental oral drug called INT-210 in adults with active ulcerative colitis, a chronic inflammatory bowel disease. Participants take either 200 mg or 400 mg of INT-210 twice daily for 12 weeks. The main goals are to check the drug's safety and how the body processes it, while also looking at whether it improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- INT-210 capsule
- What this could lead to
- If successful, INT-210 could offer a new oral treatment option to help control active ulcerative colitis and reduce symptoms.
- What could go wrong
- This is an early-phase trial with only 24 participants, so results may not apply broadly. The drug may cause side effects or prove no better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Chao-Yang Hospital, Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Luhe Hospital, Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangzhou First People's Hospital
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renmin Hospital of Wuhan University
RECRUITINGWuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Bethune Hospital
RECRUITINGTaiyuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shengjing Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Henan Medical University
RECRUITINGXinxiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weifang People's Hospital
RECRUITINGWeifang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xijing Hospital (The First Affiliated Hospital of Air Force Medical University)
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stool test may predict gut healing in ulcerative colitis
- New staining technique could sharpen healing assessment in IBD
- Real-World study tests Once-Daily pill for ulcerative colitis in chinese adults
- Can a higher dose of upadacitinib rescue ulcerative colitis patients when standard treatment fails?
- Study aims to keep workers with chronic illnesses on the job
- Real-World study tests Mirikizumab's power against ulcerative colitis